• Company
• Shingrix lead mkt again…shakes shingles vaccine mkt
• by Chon, Seung-Hyun Nov 23, 2023 05:37am

• Company
• SK Bioscience & Hilleman Laboratories develop Ebola vaccine
• by Kim, Jin-Gu Nov 23, 2023 05:37am

• Company
• Leukemia drug Xospata’s reimb limit may be resolved
• by Eo, Yun-Ho Nov 23, 2023 05:37am

• Policy
• Enspryng and Jemperli will be reimbursed through RSA
• by Lee, Tak-Sun Nov 22, 2023 05:30am

• Company
• Reimb of COVID-19 drugs necessary with eased crisis level
• by Eo, Yun-Ho Nov 22, 2023 05:30am

• Policy
• Will PE exemption drugs be reevaluated based on RWD?
• by Lee, Tak-Sun Nov 22, 2023 05:30am

• Company
• Mitsubishi’s Lou Gehrig's disease drug Radicut's sale soars
• by Nho, Byung Chul Nov 21, 2023 05:48am

• Company
• IL inhibitor reimb as 1st-line Tx for ankylosing spondylitis
• by Eo, Yun-Ho Nov 21, 2023 05:48am

• Policy
• Global bioleaders gather in Seoul for World Bio Summit
• by Lee, Jeong-Hwan Nov 21, 2023 05:48am

• Company
• Yuhan Leclaza clinical phase 3 cost exceeds 100 billion
• by Chon, Seung-Hyun Nov 20, 2023 05:50am